Last reviewed · How we verify
NCT03603847
Prospective Study of the Prognostic Value of New Markers in Adults With ALK-positive Large Anaplastic Lymphoma
trial in Anaplastic Large Cell Lymphoma, ALK-Positive in 41 participants. Completed in 16 June 2023.
16 June 2023
Quick facts
| Lead sponsor | The Lymphoma Academic Research Organisation |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 41 |
| Start date | 2 August 2018 |
| Primary completion | 16 June 2023 |
| Estimated completion | 16 June 2023 |
| Sites | 15 locations across France |
Conditions studied
- Anaplastic Large Cell Lymphoma, ALK-Positive — all drugs for Anaplastic Large Cell Lymphoma, ALK-Positive →
Sponsor
The Lymphoma Academic Research Organisation — full company profile →
Who can join
18 and older, any sex, with Anaplastic Large Cell Lymphoma, ALK-Positive. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study aims to evaluate the prognostic value on the complete metabolic response rate (MCR), the incidence of relapse / progression, the Progression Free Survival (PFS) and the Overall Survival (OS). * at diagnosis * after the first cycle of CHOEP (early evaluation) * at the end of treatment
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03603847
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Anaplastic Large Cell Lymphoma, ALK-Positive
Currently open trials in the same condition.
- NCT06176690 — Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas · Phase 1 · recruiting
- NCT07013565 — Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL · Phase 2 · active not recruiting
- NCT05978141 — A Registry for People With T-cell Lymphoma · recruiting
- NCT02978625 — Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-mela · Phase 2 · active not recruiting
- NCT03113500 — Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma · Phase 2 · active not recruiting
Other The Lymphoma Academic Research Organisation trials
Trials by the same sponsor.
- NCT06994169 — Glofitamab in Real Life · recruiting
- NCT06592846 — FERtility After Therapy With Intensive Lymphoma in Young Women: LNH-03 1B, LNH-03 2B, LNH-07 3B, GAINED Follow-up · completed
- NCT06271057 — Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse · Phase 2 · recruiting
- NCT05529524 — Signatures of Response and Resistance to Mosunetuzomab in Follicular Lymphomas (FL) · completed
- NCT04802590 — Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma · Phase 2 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03603847 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Lymphoma Academic Research Organisation
- Last refreshed: 26 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03603847.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing